Guobang Pharma EBIT

Guobang Pharma (605507.SS) currently reports a EBIT of $750M as of September 2026. That compares with $900M in the prior-year period — down 16.7% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Guobang Pharma's EBIT history and peer comparisons.

Guobang Pharma's EBIT decreased from $900M to $750M — a 16.7% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Guobang Pharma's EBIT of $750M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Guobang Pharma reported $750M in EBIT as of September 2026. That compares with $900M in the prior-year period — down 16.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $750M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Guobang Pharma, and consider following 605507.SS for alerts when major investors trade the stock.